Company
Melbourne, VIC
Every investor coverage indicates participated in a round Neuren Pharmaceuticals raised.
Companies Neuren Pharmaceuticals acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Neuren Pharmaceuticals. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
European regulators have cleared Neuren's Rett syndrome drug DAYBU, the first such treatment authorised in the EU, with milestone payments due to the Melbourne biotech from licence partner Acadia.
Melbourne drug developer Hatchtech raised A$12.6 million, with OneVentures Innovation Fund leading, to advance its head lice treatment toward Phase III trials; board changes brought in Richard Treagus and Hugh Alsop.